Advertisement

Picture Kentro Design Corporate and Web Design for Start Ups 2x 650x80px

Deals > All

Find below collaborations, license and distribution agreements, grants, investments and loan agreements in Austria, Germany and Switzerland or involving organisations from these countries.

Total search results: 3757 | Ordered by Date (descending)
next pagenext page 1 2 3 ... 36 37 38  next pagenext page

order ascendingorder descendingDeal: Collaboration or Financing order ascendingorder descendingDate
Affini-T Therapeutics–SEVERAL: investment, 202203 financing round $175m co-led by Vida Ventures + Leaps by Bayer 2022-03-22
ITM–ICIF: investment, 202203 financing round totalling €33m incl new investor Indigenous Critical Infrastructure Fund Canada 2022-03-22
ITM–Portland Holdings: investment, 202203 financing round totalling €33m incl exisiting investor PE fund managed by Portland Investment Counsel Inc 2022-03-22
ITM–SEVERAL: investment, 202203 financing round €33m from ICIF + PE fund managed by Portland Investment Counsel Inc 2022-03-22
Nucleai MD–Debiopharm: investment, 202203 financing round Series B totalling $33m incl existing + co-investor Debiopharm 2022-03-22
Nucleai MD–SEVERAL: investment, 202203 financing round Series B $33m co-led by Section 32 + Sanofi Ventures 2022-03-22
Nagi Bioscience–Switzerland (govt): grant, 202203 SERI-funded €2.5m EIC Accelerator program grant 2022-03-21
Gilde Investment–SEVERAL: investment, 202203 first + final close of €517m Gilde Healthcare Private Equity IV fund 2022-03-16
Precirix–SEVERAL: investment, 202203 financing round Series B €80 co-led by new investors Inkef Capital + Jeito Capital + Forbion 2022-03-16
BMS–Temedica: digital companion diagnostic, 202203– collab development digital companion diagnostic for psoriasis patients 2022-03-15
PrognomiQ–Bruker: investment, 202203 financing round totalling $46m incl lead investor Bruker Corp 2022-03-15
PrognomiQ–SEVERAL: investment, 202203 financing round $46m led by Bruker Corp 2022-03-15
Ayoxxa–btov Partners: investment, 202203 financing round providing runway for 3-5 years incl existing + co-investor b-to-v Partners Sàrl 2022-03-14
Ayoxxa–Equivation: investment, 202203 financing round providing runway for 3-5 years incl existing + co-investor Equivation-Beteiligungs-GmbH 2022-03-14
Ayoxxa–North Rhine-Westphalia (govt): investment, 202203 financing round providing runway for 3-5 years incl existing + co-investor NRW.Bank 2022-03-14
Ayoxxa–PERSON: investment, 202203 financing round providing runway for 3-5 years incl existing + co-investor Rainer Christine Asset Management GmbH 2022-03-14
Ayoxxa–PERSON: investment, 202203 financing round providing runway for 3-5 years incl existing + co-investor Riesner Verwaltungs GmbH 2022-03-14
Ayoxxa–Prosnav Capital: investment, 202203 financing round providing runway for 3-5 years incl new + lead investor Prosnav Capital 2022-03-14
Ayoxxa–ROI Verwaltungsgesellschaft: investment, 202203 financing round providing runway for 3-5 years incl existing + co-investor Oetker Family Office 2022-03-14
Ayoxxa–SEVERAL: investment, 202203 financing round providing runway for 3-5 years led by new investor Prosnav Capital 2022-03-14
Ayoxxa–Wellington Partners: investment, 202203 financing round providing runway for 3-5 years incl existing + co-investor Wellington Partners 2022-03-14
FGen–Ginkgo Bioworks: investment, 202203– acquisition of FGen AG by Ginkgo Bioworks for upfront payment + milestones ANNOUNCED 2022-03-14
Ginkgo Bioworks–FGen: screening technology, 202203 collab existent for several years 2022-03-14
Opto Biolabs–PERSON: investment, 202203 existent business angel investor Matthias Bissinger 2022-03-10
Opto Biolabs–PERSON: investment, 202203 existent business angel investor Philipp Baaske 2022-03-10
Roche–Scenic Biotech: drugs targeting genetic modifiers, 202203 collab multi-year multi-target existent with Genentech 2022-03-10
Scenic Biotech–BioMedPartners: investment, 202203 financing round Series A totalling €28m incl new + co-lead investor BioMedPartners 2022-03-10
Scenic Biotech–SEVERAL: investment, 202203 financing round Series A €28m co-led by Eir Ventures + BioMedPartners + Vesalius Biocapital 2022-03-10
Merck (DE)–Celeris Therapeutics: AI-based drug discovery, 202202– collab research small molecule binders + bifunctional degraders 2022-03-09
NEC–Vaximm: cancer vaccines, 202203 acquisition of all neoantigen cancer vaccines assets by NEC OncoImmunity 2022-03-08
Eurazeo–SEVERAL: investment, 202203 first closing €160m of Kurma Partners Growth Opportunities Fund targeting €250m 2022-03-07
Proteona–Singleron: investment, 202203 acquisition of Proteona Pte Ltd by Singleron Biotechnologies 2022-03-07
ArrePath–Boehringer: investment, 202203 seed financing round totalling $20m incl co-lead investor BIVF 2022-03-03
ArrePath–SEVERAL: investment, 202203 seed financing round $20m co-led by BIVF + Insight Partners + Innospark Ventures 2022-03-03
Epsilogen–Novartis: investment, 202203 financing round Series B totalling £30.75m incl new + lead investor Novartis Venture Fund 2022-03-02
Epsilogen–SEVERAL: investment, 202203 financing round Series B £30.75m led by new investor Novartis Venture Fund 2022-03-02
BioEcho Life Sciences–Ampersand: investment, 202203 minority growth equity investment €na from Ampersand Capital Partners 2022-03-01
In Ovo–ABN AMRO: investment, 202203 financing round totalling €34m incl new investor ABN AMRO 2022-03-01
In Ovo–ECBF: investment, 202203 financing round totalling €34m incl new investor ECBF 2022-03-01
In Ovo–Evonik: investment, 202203 financing round totalling €34m incl existing investor Evonik 2022-03-01
In Ovo–SEVERAL: investment, 202203 financing round €34m with ECBF + ABN AMRO et al 2022-03-01
Aphea.Bio–ECBF: investment, 202202 existent investment of ECBF 2022-02-23
Ampersand–Recipharm: investment, 202202– acquisition of Vibalogics by Recipharma AB ANNOUNCED 2022-02-18
Centauri Therapeutics–SEVERAL: investment, 202202 financing round Series A £24m with BIVF + Evotec + Novo REPAIR Impact Fund et al 2022-02-16
Climedo Health–SEVERAL: investment, 202202 seed financing round €5m led by Nauta Capital 2022-02-16
ITM–Grand Pharma: investment, 202202 equity investment €25m from strategic partner Grand Pharmaceutical Group Ltd 2022-02-16
SpliceBio–SEVERAL: investment, 202202 financing round Series A €50m co-led by UCB Ventures + Ysios Capital 2022-02-16
XO Life–SEVERAL: investment, 202202 financing round more than €2m from SeedLink + MediVentures + Aescuvest et al 2022-02-16
c-LEcta–Kerry Group: investment, 202202 acquisition 92% for €137m with management to retain balance of shares 2022-02-15
IMIDomics–Evotec: investment, 202202 strategic equity investment €na by Evotec 2022-02-15
NMD Pharma–Roche: investment, 202202 financing round totalling €35m incl existing + co-investor Roche Venture Fund 2022-02-15
NMD Pharma–SEVERAL: investment, 202202 financing round €35m led by new investor Jeito Capital + incl existing investors 2022-02-15
Sequana Medical –Newton Biocapital: investment, before 202202 former pre-IPO early-exit investment of NBC I fund 2022-02-15
Green Elephant Biotech–Hessen (govt): investment, 202201 pre-seed financing round totalling mid-6-digit € incl lead investor BMH 2022-02-11
Green Elephant Biotech–OTHER: investment, 202201 pre-seed financing round totalling mid-6-digit € incl business angels as co-investors 2022-02-11
Green Elephant Biotech–SEVERAL: investment, 202201 pre-seed financing round mid-6-digit € led by BMH with business angels 2022-02-11
Celeris Therapeutics–Apex Ventures: investment, 202202 seed financing round totalling $4.4m incl new + co-lead investor Apex Ventures 2022-02-10
Celeris Therapeutics–i&i Biotech Fund: investment, 202202 seed financing round totalling $4.4m incl new + co-lead investor i&i Biotech Fund 2022-02-10
Celeris Therapeutics–Longevitytech.fund: investment, 202202 seed financing round totalling $4.4m incl existing + co-investor Longevitytech.fund 2022-02-10
Celeris Therapeutics–Pace Ventures Enigma: investment, 202202 seed financing round totalling $4.4m incl new + co-lead investor Pace Ventures Enigma 2022-02-10
Celeris Therapeutics–R42 Group: investment, 202202 seed financing round totalling $4.4m incl existing + co-investor R42 Group 2022-02-10
Celeris Therapeutics–SEVERAL: investment, 202202 seed financing round $4.4m led by Pace Ventures Enigma + i&i Biotech Fund + Apex Ventures 2022-02-10
Haya Therapeutics–4See Ventures: investment, 202202 seed financing round extension totalling $5m incl existing + co-investor 4See Ventures 2022-02-09
Haya Therapeutics–Apollo Ventures: investment, 202202 seed financing round extension totalling $5m incl existing + co-investor Apollo Health Ventures 2022-02-09
Haya Therapeutics–Bernina BioInvest: investment, 202202 seed financing round extension totalling $5m incl existing + co-investor Bernina BioInvest 2022-02-09
Haya Therapeutics–Broadview Ventures: investment, 202202 seed financing round extension totalling $5m incl existing + co-investor Broadview Ventures 2022-02-09
Haya Therapeutics–Humboldt Fund: investment, 202202 seed financing round extension totalling $5m incl new + lead investor Humboldt Fund 2022-02-09
Haya Therapeutics–Schroders: investment, 202202 seed financing round extension totalling $5m incl existing + co-investor Schroder Adveq 2022-02-09
Haya Therapeutics–SEVERAL: investment, 202202 seed financing round extension $5m led by new investor Humboldt Fund 2022-02-09
Haya Therapeutics–Viva Biotech: investment, 202202 seed financing round extension totalling $5m incl existing + co-investor Viva BioInnovator 2022-02-09
Lindis Blood Care–Brandenburg (govt): investment, 202202 follow-on financing round incl existing + co-lead investor Brandenburg Kapital 2022-02-09
Lindis Blood Care–High-Tech Gründerfonds: investment, 202202 follow-on financing round incl existing + co-lead investor HTGF 2022-02-09
Lindis Blood Care–MC Services: public relations, 202202 service existent by MC Services 2022-02-09
Lindis Blood Care–OTHER: investment, 202202 follow-on financing round incl several private investors 2022-02-09
Lindis Blood Care–SEVERAL: investment, 202202 follow-on financing round led by HTGF + Brandenburg Kapital + several private investors 2022-02-09
Protix–ECBF: investment, 202202 financing round totalling €50m incl investor ECBF 2022-02-09
Protix–SEVERAL: investment, 202202 financing round €50m from ECBF + BNP Paribas et al 2022-02-09
Formo–BRAIN Biotech: genome editing technology, 202202– collab using CRISPR BEC platform to scale production of bioidentical milk protein 2022-02-08
In-Part–Inova Software: investment, 202202 acquisition of In-Part by Inova 2022-02-08
Elicit Plant–ECBF: investment, 202202 equity component €na of €16m funding round incl co-investor ECBF 2022-02-07
Elicit Plant–SEVERAL: investment, 202202 equity component €na led by Sofinnova Partners as part of funding round totalling €16m 2022-02-07
iOmx Therapeutics–MC Services: public relations, 202202 service existent by MC Services 2022-02-03
Merck (DE)–eTheRNA: mRNA technology, 202202– collab research using eTheRNA’s mRNA + LNP technologies to evaluate therapeutic feasibility 2022-02-03
Nemis Technologies–SEVERAL: investment, 202202 financing round Series A CHF7.75m from institutional + private investors 2022-02-03
Weriol Group–BRAIN Biotech: investment, 202202 acquisition of 62% of Breatec/Comix for €3.7m upfront + option to acquire remaining shares until 2027Q1 2022-02-03
Ethris–Laureus Capital: investment, 202201 financing round Series B totalling €23.3m inc lead investor Laureus Capital 2022-02-01
Ethris–SEVERAL: investment, 202201 financing round Series B €23.3m led by Laureus Capital 2022-02-01
Ethris–Trophic Communications: public relations, 202201 service existent by Trophic 2022-02-01
myPOLS Biotec–Medix Biochemica: investment, 202202 acquisition 100% of myPOLS Biotec GmbH by Medix Biochemica 2022-02-01
Noventi–Temedica: healthcare data analytics, 202202– collab using Permea system to advance healthcare research with real-world data 2022-02-01
Pharvaris–BRAIN Biotech: drug discovery services, 202202–202307 collab extension 9 months RnD bradykinin-B2-receptor antagonists Analyticon Discovery 2022-02-01
Zetta Genomics–SEVERAL: investment, 202202 seed financing round £2.5m with Cambridge Enterprise + Apex Ventures + Nina Capital 2022-02-01
Gandeeva Therapeutics–Bayer: investment, 202201 financing round Series A totalling $40m incl co-lead investor Leaps by Bayer 2022-01-31
Gandeeva Therapeutics–SEVERAL: investment, 202201 financing round Series A $40m led by Lux Capital + Leaps by Bayer 2022-01-31
Ribbon Biolabs–SEVERAL: investment, 202201 financing round Series A €18m led by Hadean Ventures 2022-01-31
Ribbon Biolabs–Trophic Communications: public relations, 202201 service existent by Trophic 2022-01-31
xbird–Glooko: investment, 202201 acquisition of xbird GmbH by Glooko Inc 2022-01-31
Mainz Biomed–SEVERAL: investment, 202201 public follow-on offering $22.5m+$3.375m with 1.725m+225k common shares at $15/share 2022-01-28
Cellino–Bayer: investment, 202201 financing round Series A totalling $80m incl new + lead investor Leaps by Bayer 2022-01-25
Cellino–SEVERAL: investment, 202201 financing round Series A $80m led by Leaps by Bayer + 8VC + Humboldt Fund 2022-01-25
next pagenext page 1 2 3 ... 36 37 38  next pagenext page



Advertisement

Picture [iito] Männer Ballett 650x100px

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]

Please visit also our web portals for the European life sciences and the worldwide mass spectrometry industry at Life-Sciences-Europe.com (European life sciences) and Mass-Spec-Capital.com (worldwide mass spectrometry)

Please visit also our web portals for the life sciences in German-speaking Europe (DE, AT & CH) and the worldwide mass spectrometry industry at Life-Sciences-Germany.com (life sciences in German-speaking Europe) and Mass-Spec-Capital.com (worldwide mass spectrometry)


Advertisement

Picture [iito] [LSE] Life-Sciences-Europe.com Business Portal 650x300px

» top